← Back to front page
United States · Wires & real time · PR Newswire

Akeso's Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis

Published by PR Newswire · United States 1 h ago
Akeso's Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis
PR Newswire

Detailed summary

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug…

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for gumokimab, its self-developed IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). Active AS marks the second approved indication for gumokimab. In June 2026, gumokimab received approval in China for moderate-to-severe plaque psoriasis.

The AS approval is supported by the positive results of the pivotal Phase 3 registration study AK111-303. The study met all pre-specified efficacy endpoints, demonstrating that gumokimab provides rapid, robust, and sustained relief of AS symptoms while significantly improving disease activity, physical function, and quality of life.

Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the sacroiliac joints, spine, and peripheral joints. In severe cases, it can result in spinal deformity and functional impairment, substantially impacting patients' quality of life. IL-17A is a key pro-inflammatory cytokine implicated in the pathogenesis of autoimmune diseases such as psoriasis and ankylosing spondylitis. Gumokimab binds specifically and with high affinity to human IL-17A, blocking its interaction with IL-17 receptor A (IL-17RA) expressed on T cells, natural killer cells, and antigen-presenting cells, thereby inhibiting the downstream inflammatory cascade.

Professor Rong Mu, Principal Investigator of AK111-303 and Professor at Peking University Third Hospital, stated: "Clinical management of this disease continues to present significant challenges, and current treatment options do not fully address patients' needs regarding depth of response, long-term disease control, and accessibility.

Dr. Michelle Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso, commented: "We extend our sincere thanks to the investigators, study teams, and patients who participated in the…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading